IL181919A - 1CoLE plasmid vector-surrogate system free from antibiotics that includes a plasmid with a CoLE1 replication source and a bacterial surrogate cell and methods using the above system - Google Patents
1CoLE plasmid vector-surrogate system free from antibiotics that includes a plasmid with a CoLE1 replication source and a bacterial surrogate cell and methods using the above systemInfo
- Publication number
- IL181919A IL181919A IL181919A IL18191907A IL181919A IL 181919 A IL181919 A IL 181919A IL 181919 A IL181919 A IL 181919A IL 18191907 A IL18191907 A IL 18191907A IL 181919 A IL181919 A IL 181919A
- Authority
- IL
- Israel
- Prior art keywords
- plasmid
- protein
- rna
- gene
- cell
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims description 218
- 230000001580 bacterial effect Effects 0.000 title claims description 65
- 230000010076 replication Effects 0.000 title claims description 45
- 239000013598 vector Substances 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 258
- 210000004027 cell Anatomy 0.000 claims description 121
- 239000003550 marker Substances 0.000 claims description 94
- 230000014509 gene expression Effects 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 87
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 85
- 108020004414 DNA Proteins 0.000 claims description 79
- 108091030071 RNAI Proteins 0.000 claims description 72
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 62
- 231100000331 toxic Toxicity 0.000 claims description 49
- 230000002588 toxic effect Effects 0.000 claims description 49
- 241000588724 Escherichia coli Species 0.000 claims description 35
- 108700039887 Essential Genes Proteins 0.000 claims description 28
- 231100000518 lethal Toxicity 0.000 claims description 26
- 230000001665 lethal effect Effects 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 230000001939 inductive effect Effects 0.000 claims description 25
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 230000012010 growth Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 14
- 210000003705 ribosome Anatomy 0.000 claims description 14
- 108091081024 Start codon Proteins 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 108010034634 Repressor Proteins Proteins 0.000 claims description 5
- 102000009661 Repressor Proteins Human genes 0.000 claims description 5
- 230000000754 repressing effect Effects 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000009036 growth inhibition Effects 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 description 55
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 53
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 53
- 108020004999 messenger RNA Proteins 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 230000014616 translation Effects 0.000 description 18
- 230000003993 interaction Effects 0.000 description 17
- 230000006698 induction Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- COAABSMONFNYQH-TTWCUHKNSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(oxiran-2-ylmethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1SCC1OC1 COAABSMONFNYQH-TTWCUHKNSA-N 0.000 description 13
- 230000003115 biocidal effect Effects 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 101150089003 murA2 gene Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003828 downregulation Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 11
- 239000000411 inducer Substances 0.000 description 11
- 101100239088 Bacillus subtilis (strain 168) murAA gene Proteins 0.000 description 10
- 101100131847 Bacillus subtilis (strain 168) murAB gene Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 101150025333 murA gene Proteins 0.000 description 10
- 101150023205 murA1 gene Proteins 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000003184 complementary RNA Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108020005544 Antisense RNA Proteins 0.000 description 7
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 210000003578 bacterial chromosome Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 101150061166 tetR gene Proteins 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000037440 gene silencing effect Effects 0.000 description 4
- 238000013383 initial experiment Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 101150025220 sacB gene Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 3
- 108010046276 FLP recombinase Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 3
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 238000012366 Fed-batch cultivation Methods 0.000 description 2
- 108010036940 Levansucrase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000701245 Paramecium bursaria Chlorella virus 1 Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 101100075995 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fma2 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 101150117187 glmS gene Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- SGWFGVQCRDTUQN-UHFFFAOYSA-N (2-prop-2-ynoyloxy-3-prop-2-ynoylsulfanylpropyl) prop-2-ynoate Chemical compound C#CC(=O)OCC(OC(=O)C#C)CSC(=O)C#C SGWFGVQCRDTUQN-UHFFFAOYSA-N 0.000 description 1
- 101710192508 30S ribosomal protein S2 Proteins 0.000 description 1
- 108050003931 30S ribosomal proteins Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100021029 Activating signal cointegrator 1 complex subunit 3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 101000755953 Bacillus subtilis (strain 168) Ribosome maturation factor RimP Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000722731 Carex Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710174557 DEAD-box ATP-dependent RNA helicase 29 Proteins 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 102000006465 DNA Restriction-Modification Enzymes Human genes 0.000 description 1
- 108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101100180053 Danio rerio isl2b gene Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108700034853 E coli TRPR Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100285515 Escherichia coli (strain K12) hokD gene Proteins 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101150064138 MAP1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101100098966 Mus musculus Ticam2 gene Proteins 0.000 description 1
- 101100468245 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) relF gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101100443856 Streptococcus pyogenes serotype M18 (strain MGAS8232) polC gene Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108091029855 T44 RNA Proteins 0.000 description 1
- 101710120203 Tetracycline resistance determinant Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010085193 UDP-N-acetylglucosamine 1-carboxyvinyltransferase Proteins 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- DLRVVLDZNNYCBX-CAPXFGMSSA-N allolactose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)O1 DLRVVLDZNNYCBX-CAPXFGMSSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150027005 divIB gene Proteins 0.000 description 1
- 101150008507 dnaE gene Proteins 0.000 description 1
- 101150035285 dnaE1 gene Proteins 0.000 description 1
- 101150003155 dnaG gene Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 101150012763 endA gene Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 101150101609 ftsA gene Proteins 0.000 description 1
- 101150002100 ftsK gene Proteins 0.000 description 1
- 101150026421 ftsQ gene Proteins 0.000 description 1
- 101150111615 ftsZ gene Proteins 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 101150023479 hsdS gene Proteins 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 101150112095 map gene Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102220311690 rs771555522 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04022201 | 2004-09-17 | ||
| PCT/EP2005/054450 WO2006029985A2 (en) | 2004-09-17 | 2005-09-08 | Host-vector system for antibiotic-free cole1 plasmid propagation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL181919A0 IL181919A0 (en) | 2007-07-04 |
| IL181919A true IL181919A (en) | 2012-04-30 |
Family
ID=34926585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL181919A IL181919A (en) | 2004-09-17 | 2007-03-14 | 1CoLE plasmid vector-surrogate system free from antibiotics that includes a plasmid with a CoLE1 replication source and a bacterial surrogate cell and methods using the above system |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060063232A1 (enExample) |
| EP (1) | EP1794299B1 (enExample) |
| JP (1) | JP5301832B2 (enExample) |
| KR (2) | KR101023066B1 (enExample) |
| CN (2) | CN103555644B (enExample) |
| AR (2) | AR050649A1 (enExample) |
| AU (1) | AU2005284136B2 (enExample) |
| BR (1) | BRPI0515436A (enExample) |
| CA (1) | CA2580009C (enExample) |
| IL (1) | IL181919A (enExample) |
| NZ (1) | NZ554236A (enExample) |
| TW (1) | TWI311152B (enExample) |
| WO (1) | WO2006029985A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327056D0 (en) * | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
| AU2008252990B2 (en) | 2007-05-17 | 2015-01-15 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Method for producing a recombinant protein on a manufacturing scale |
| EP2152889B1 (en) * | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| EP2173879A4 (en) * | 2007-07-16 | 2010-10-20 | Royal Veterinary College | GEN / INHIBITOR COMBINATIONS WITH MUTUAL SUPPRESSION FOR THE ANTIBIOTIC-FREE SELECTION OF RECOMBINANT STRAINS |
| JP5538691B2 (ja) * | 2007-11-22 | 2014-07-02 | 独立行政法人科学技術振興機構 | Ｒｎａ−蛋白質相互作用モチーフを利用した蛋白質応答翻訳制御システム |
| EP2500427B1 (en) | 2007-11-22 | 2014-07-30 | Japan Science and Technology Agency | Translation regulation system in cell or artifical cell model by using low-molecular-weight RNA |
| HUE031597T2 (en) * | 2009-05-22 | 2017-07-28 | Merial Inc | Antibiotic-free plasmid |
| US20110269184A1 (en) | 2009-07-16 | 2011-11-03 | Boehringer Ingelheim Rcv Gmbh & Co. Kg | Method for controlling plasmid copy number in e.coli |
| WO2012082946A2 (en) * | 2010-12-14 | 2012-06-21 | The Regents Of The University Of California | Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations. |
| GB201021795D0 (en) * | 2010-12-21 | 2011-02-02 | Msd Biolog Uk Ltd | Expression Process |
| EP2890404B1 (en) | 2012-08-29 | 2018-06-13 | Nature Technology Corporation | Dna plasmids with improved expression |
| WO2014077863A1 (en) | 2012-11-19 | 2014-05-22 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
| JP7161991B2 (ja) * | 2016-11-02 | 2022-10-27 | アーチャーディーエックス， エルエルシー | 免疫レパートリーシーケンシングのための核酸サンプル調製の方法 |
| CN107142272A (zh) * | 2017-06-05 | 2017-09-08 | 南京金斯瑞生物科技有限公司 | 一种控制大肠杆菌中质粒复制的方法 |
| DK3456821T4 (da) | 2017-09-19 | 2024-04-15 | Deutsches Krebsforsch | Ikke-integrerende dna-vektorer til genetisk modifikation af celler |
| WO2019057774A1 (en) | 2017-09-19 | 2019-03-28 | Deutsches Krebsforschungszentrum | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS |
| JP7520719B2 (ja) | 2018-03-21 | 2024-07-23 | アルデブロン，エル．エル．シー． | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
| JP7661015B2 (ja) | 2020-06-12 | 2025-04-14 | ナガセヴィータ株式会社 | 目的タンパク質の製造方法 |
| WO2023166132A1 (en) * | 2022-03-04 | 2023-09-07 | Gen-H Genetic Engineering Heidelberg Gmbh | Microorganism strain for antibiotic-free plasmid-based fermentation and method for generation thereof |
| CN117187281A (zh) * | 2023-09-11 | 2023-12-08 | 云舟生物科技(广州)股份有限公司 | 一种无抗性质粒生产系统及其应用 |
| CN118028194B (zh) * | 2023-12-26 | 2024-09-06 | 浙江大学 | 基因组精简的恶臭假单胞菌菌株 |
| WO2025160245A1 (en) | 2024-01-25 | 2025-07-31 | Aldevron, L.L.C. | Viral and non-viral nanoplasmid vectors with improved production |
| WO2025231315A2 (en) | 2024-05-03 | 2025-11-06 | Aldevron, L.L.C. | Bacterial host strains |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9215541D0 (en) * | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5922583A (en) * | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
| EP1195436A1 (en) | 2000-10-04 | 2002-04-10 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Expression vectors with modified ColE1 origin of replication for control of plasmid copy number |
| US20040248083A1 (en) * | 2001-05-17 | 2004-12-09 | Mikkelsen Jacob Giehm | Vectors for gene therapy |
| SE0102204D0 (sv) * | 2001-06-21 | 2001-06-21 | Leif Isaksson | New method |
| CN1490056A (zh) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
| GB0327056D0 (en) | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
-
2005
- 2005-09-06 TW TW94130459A patent/TWI311152B/zh not_active IP Right Cessation
- 2005-09-08 JP JP2007531743A patent/JP5301832B2/ja not_active Expired - Lifetime
- 2005-09-08 BR BRPI0515436-7A patent/BRPI0515436A/pt not_active IP Right Cessation
- 2005-09-08 CN CN201310409070.8A patent/CN103555644B/zh not_active Expired - Lifetime
- 2005-09-08 WO PCT/EP2005/054450 patent/WO2006029985A2/en not_active Ceased
- 2005-09-08 KR KR20077007467A patent/KR101023066B1/ko not_active Expired - Lifetime
- 2005-09-08 CN CNA2005800377789A patent/CN101052722A/zh active Pending
- 2005-09-08 CA CA 2580009 patent/CA2580009C/en not_active Expired - Lifetime
- 2005-09-08 KR KR1020107017286A patent/KR20100101689A/ko not_active Ceased
- 2005-09-08 NZ NZ554236A patent/NZ554236A/en not_active IP Right Cessation
- 2005-09-08 AU AU2005284136A patent/AU2005284136B2/en not_active Expired
- 2005-09-08 EP EP05789661.5A patent/EP1794299B1/en not_active Expired - Lifetime
- 2005-09-14 US US11/226,795 patent/US20060063232A1/en not_active Abandoned
- 2005-09-19 AR ARP050103886 patent/AR050649A1/es not_active Application Discontinuation
-
2007
- 2007-03-14 IL IL181919A patent/IL181919A/en not_active IP Right Cessation
-
2008
- 2008-10-28 US US12/259,662 patent/US9297014B2/en active Active
-
2011
- 2011-01-21 AR ARP110100203 patent/AR079958A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2580009C (en) | 2013-12-17 |
| AR050649A1 (es) | 2006-11-08 |
| AU2005284136B2 (en) | 2011-07-14 |
| TWI311152B (en) | 2009-06-21 |
| TW200621985A (en) | 2006-07-01 |
| KR101023066B1 (ko) | 2011-03-24 |
| AU2005284136A1 (en) | 2006-03-23 |
| CN103555644A (zh) | 2014-02-05 |
| US20090263861A1 (en) | 2009-10-22 |
| KR20100101689A (ko) | 2010-09-17 |
| EP1794299A2 (en) | 2007-06-13 |
| KR20070059130A (ko) | 2007-06-11 |
| NZ554236A (en) | 2010-05-28 |
| WO2006029985A3 (en) | 2006-07-27 |
| EP1794299B1 (en) | 2015-09-02 |
| CN101052722A (zh) | 2007-10-10 |
| US9297014B2 (en) | 2016-03-29 |
| BRPI0515436A (pt) | 2008-07-22 |
| AR079958A2 (es) | 2012-02-29 |
| JP2008512998A (ja) | 2008-05-01 |
| US20060063232A1 (en) | 2006-03-23 |
| IL181919A0 (en) | 2007-07-04 |
| CN103555644B (zh) | 2018-06-01 |
| JP5301832B2 (ja) | 2013-09-25 |
| WO2006029985A2 (en) | 2006-03-23 |
| CA2580009A1 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9297014B2 (en) | Host-vector system antibiotic-free ColE1 plasmid propagation | |
| Williams et al. | Generic plasmid DNA production platform incorporating low metabolic burden seed‐stock and fed‐batch fermentation processes | |
| JP2005523015A (ja) | 種々の遺伝子発現レベルを有する細菌クローンのライブラリーを構築する方法。 | |
| US20190032048A1 (en) | Improved cloning and expression vectors and systems | |
| CA2358263A1 (en) | Methods | |
| KR102688555B1 (ko) | CRISPR/Cpf1 시스템을 기반으로 한 유전체 단일 염기 편집 방법 및 이의 용도 | |
| CN113621635A (zh) | 用于自诱导蛋白表达的方法和系统 | |
| EP1924693B1 (en) | Hybrid portable origin of replication plasmids | |
| PL222067B1 (pl) | Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor ekspresyjny, komórka prokariotycznego gospodarza zawierająca wektor ekspresyjny, szczep bakteryjny oraz sposób wytwarzania polipeptydu | |
| US20110269184A1 (en) | Method for controlling plasmid copy number in e.coli | |
| US20030003525A1 (en) | Novel promoter of gene expression | |
| JP5422804B2 (ja) | 外来ｄｎａ断片由来の逆方向反復配列を含む組換えベクター及びその作製方法 | |
| JP2025507940A (ja) | 抗生物質を含まないプラスミドベースの発酵のための微生物株及びその生成方法 | |
| MX2007003110A (en) | Host-vector system for antibiotic-free cole1 plasmid propagation | |
| Balbás et al. | Molecular cloning by plasmid vectors | |
| US8999672B2 (en) | Compositions and processes for improved plasmid DNA production | |
| EP1706490A2 (en) | Systems for tightly regulated gene expression | |
| Zh et al. | Design and study on characteristics of auto-and smoothly regulated genetic element O3/PlacUV5/Olac→ lacI | |
| KR20250042179A (ko) | CRISPR-Cas9-기반의 플라스미드 DNA 주형의 선형화 | |
| RU2312146C1 (ru) | Вектор на основе репликона бактериофага n15 и рекомбинантный вектор для регулируемой экспрессии целевого гена в клетках escherichia coli, штамм escherichia coli, обеспечивающий возможность регуляции числа копий вектора, и система экспрессии | |
| Geist et al. | TraM protein of plasmid R1: in vitro selection of the target region reveals two consensus 7 bp binding motifs spaced by a 4 bp linker of defined sequence | |
| Clubbe | Serine integrase-based “landing pad” systems for chromosomal integrations of heterologous genes in Escherichia coli | |
| Zolotukhina et al. | Mutational Analysis of a Leader Region of the Escherichia coli ribB Gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |